Suggested remit: To appraise the clinical and cost effectiveness of Odevixibat (A 4250) within its marketing authorisation for treating progressive familial intrahepatic cholestasis.
Status
|
In progress
|
Process |
HST
|
ID number |
1570
|
Provisional Schedule
Committee meeting: 1 |
05 August 2021 |
Expected publication |
22 January 2022 |
Project Team
Project lead |
Joanne Ekeledo |
Email enquiries
Evidence Review Group / Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Consultees
Companies sponsors |
Albireo (obevixibat) |
Others |
Department of Health and Social Care |
|
NHS England |
|
Addenbrooke's Paediatric Gastrohepatology |
|
Birmingham Children’s Hospital NHS Foundation Trust |
|
Department of Endocrinology, University Hospital Birmingham Foundation Trust Paediatric Gastrohepatology |
|
King’s College Hospital NHS Foundation Trust |
|
Leeds Teaching Hospitals NHS Trust |
|
Great Ormond Street Paediatric Gastrohepatology |
|
Royal Free Paediatric Gastrohepatology |
|
Welsh Government |
Patient carer groups |
Action for Sick Children |
|
Addenbrookes Liver Transplant Association |
|
British Liver Trust |
|
Children’s Liver Disease Foundation |
|
Contact |
|
Genetic Alliance UK |
|
Findacure |
|
Liver4Life |
|
Metabolic Support UK |
|
Muslim Council of Great Britain |
|
National Children’s Bureau |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
Professional groups |
British Association for the Study of the Liver |
|
British Liver Nurses Forum |
|
British Society of Gastroenterology |
|
British Society of Paediatric Gastroenterology, Hepatology and Nutrition |
|
British Transplantation Society |
|
Neonatal and Paediatric Pharmacists Group |
|
Royal College of Physicians |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Paediatrics and Child Health |
|
Royal Pharmaceutical Society |
|
UK Clinical Pharmacy Association |
Commentators
Associated public health groups |
Public Health England |
|
Public Health Wales |
Comparator companies |
None |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Hospital Information Services - Jehovah's Witnesses |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
National Pharmacy Association |
|
National Services Division (specialised services in Scotland) |
|
NHS Alliance |
|
NHS Confederation |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Cochrane Hepato-Biliary Group |
|
Foundation for Liver Research |
|
Genomics England |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |
|
UK National Screening Committee |
Date
|
Update
|
02 March 2021
|
Invitation to participate |
02 March 2021
|
In progress. In progress |
15 July 2020 - 12 August 2020
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance